• BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
FinanceTime
  • August 19th, 2026

FinanceTimeFinancetime

  • BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
Mifepristone, the first medication in a medical abortion, is prepared for a patient at Alamo Women's Clinic in Carbondale, Illinois, U.S., April 20, 2023. Evelyn Hockstein
Mifepristone, the first medication in a medical abortion, is prepared for a patient at Alamo Women's Clinic in Carbondale, Illinois, U.S., April 20, 2023. Evelyn Hockstein
Home
Litigation

Abortion pill manufacturer takes dispute over access to US Supreme Court

September 8th, 2023 | 19:37 PM Litigation 3

Facebook Twitter Google+ LinkedIn Pinterest

Worth reading...

Abbott settles appeal over $495 million infant formula verdict
Maine governor says NextEra-Dominion merger will limit competition, raise energy cost concerns
Indian regulator inspects Pernod plant, collects whisky samples in wider industry probe
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results
By Andrew Chung

The manufacturer of the abortion pill mifepristone asked the U.S. Supreme Court on Friday to preserve broad access to the drug as the company appealed a lower court's ruling that would curb how the medication is delivered and distributed.

Danco Laboratories said it filed its appeal of an August decision by the New Orleans-based 5th U.S. Circuit Court of Appeals that would bar telemedicine prescriptions and shipments of mifepristone by mail.

President Joe Biden's administration has said it plans to appeal the 5th Circuit's decision as well. The decision is on hold pending the outcome of the administration's appeal.

The case could put at risk the authority of the U.S. Food and Drug Administration (FDA), the federal agency that signs off on the safety of food products, drugs and medical devices. The FDA approved mifepristone in 2000.

In its filing, Danco's attorney Jessica Ellsworth said the 5th Circuit upended the approved conditions for use of Danco's drug, called Mifeprex, "at the request of a group of plaintiffs who do not prescribe or use the drug and whose real disagreement with FDA is that they oppose all forms of abortion."

If the justices decide to take up the case, they could hear arguments in their next term, which begins in October, and issue a ruling by the end of June 2024.

The 5th Circuit's decision partially sided with the anti-abortion groups and doctors who challenged mifepristone. It did not go as far as a prior decision by U.S. Judge Matthew Kacsmaryk in Amarillo, Texas, that would have suspended FDA approval of mifepristone and effectively pulled it off the market.

In April, the Supreme Court granted emergency requests by the Justice Department and the pill's manufacturer Danco Laboratories to put on hold Kacsmaryk's order while litigation continued.

Biden's administration is seeking to defend mifepristone in the face of mounting abortion bans and restrictions enacted by Republican-led states since the Supreme Court in June 2022 overturned the landmark 1973 Roe v. Wade decision that had legalized the procedure nationwide.

Mifepristone is taken with another drug called misoprostol to perform medication abortion, which accounts for more than half of all U.S. abortions. The drug has other uses including management of miscarriages. The FDA has called mifepristone safe and effective as demonstrated over decades of use by millions of Americans, with adverse effects exceedingly rare.

Anti-abortion groups led by the Alliance for Hippocratic Medicine and four anti-abortion doctors sued the FDA last year. The challengers, represented by the conservative religious rights group Alliance Defending Freedom, contend that the FDA illegally approved mifepristone and then removed critical safeguards on what they call a dangerous drug.

The 5th Circuit's August decision rolled back FDA actions that had made the drug easier to access in recent years, including a 2021 decision allowing the drug to be prescribed remotely and sent by mail, instead of requiring an in-person doctor visit, and a 2016 decision to allow mifepristone to be used to 10 weeks of pregnancy, up from seven.

Since last year's Supreme Court decision, at least 14 U.S. states have put in place outright abortion bans while many others prohibit abortion after a certain length of pregnancy.

  • Topic
  • USA
  • COURT/ABORTION
  • PILL (PIX)
Facebook Twitter Google+ LinkedIn Pinterest
Previous article Abbott settles appeal over $495 million infant formula verdict

Related Posts

Litigation
August 19th, 2026

Abbott settles appeal over $495 million infant formula verdict

Litigation
August 19th, 2026

Maine governor says NextEra-Dominion merger will limit competition, rais...

Litigation
August 19th, 2026

Indian regulator inspects Pernod plant, collects whisky samples in wider...

Litigation
August 19th, 2026

VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts aw...

Litigation
August 19th, 2026

Greater regulatory scrutiny no bar to mining mergers, bosses say

Litigation
August 19th, 2026

Moderna shares surge as melanoma vaccine with Merck succeeds in large tr...

The Wire
Aug 19th 3 h ago
Government

DOJ argues Comey novel shows he knew ‘86 47’ post was a thr...

Aug 19th 3 h ago
Business

Fed policymakers' inflation concerns increased at July meet...

Aug 19th 3 h ago
Sports

Swiss rider Poncini dies in Manx GP qualifying

Aug 19th 3 h ago
Business

Amazon plans drone delivery expansion to about 500 US local...

Aug 19th 3 h ago
Litigation

Abbott settles appeal over $495 million infant formula verd...

TRENDING ON FINANCETIME
Aug 19th, 2026 Sports

Mets' Jorge Polanco (ankle) to have season-ending surgery

Aug 19th, 2026 Sports

Reports: Phillies sign free agent LHP Nestor Cortes

Aug 19th, 2026 Business

US CFTC seeks comment on compute derivatives as AI demand grows

Aug 19th, 2026 Technology

Payments firm Stripe to buy AI developer platform OpenRouter

Aug 19th, 2026 Government

ABC says intimidation by Trump's FCC forced programming changes

Markets-Sectors
ENERGY -0.01%

  • BUSINESS
  • MARKETS
  • WORLD
  • POLITICS
  • TECH
  • COMMENTARY
  • BREAKINGVIEWS
  • MONEY
  • LIFE
  • SECTORS
  • Back to top
FinanceTime
FinanceTime

World Business & Financial News, Breaking US & International News

Additional Services
  • Privacy-Policy
  • Terms and Conditions
© Financetime.org 2026. All rights reserved. Hosted by LeadsDeposit.com
Produced by C-iT